The Role of Minor Signs in Atopic Dermatitis Diagnostics
https://doi.org/10.15690/vsp.v19i3.2120
Abstract
General information on atopic dermatitis (AD), its history and epidemiological significance are presented. Multiple etiopathogenetic factors affecting disease manifestation are identified. The absence of specific tests, laboratory and histological studies, that can help in correct AT diagnosis, is mentioned. Most of AT diagnostic schemes clarify main (major) and additional (minor) signs of disease. Clinical manifestations of AD minor signs crucial for revealing of subacute and chronic course, as well as onset of incomplete remission of disease are described. Topical AD management regimens are presented. Pathogenetic verifications for emollients and regenerating agents use are presented.
Supporting agencies: The article has been funded by Pierre Fabre.
About the Authors
Olga B. Tamrazova
Peoples' Friendship University of Russia;
Bashlyaeva Children’s City Clinical Hospital
Russian Federation
Moscow
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Olga B. Tamrazova — receiving research grants and fees for scientific counselling and lecturing from pharmaceutical companies Bayer, Weleda, Expanscience, Leofarma, La Roche- Posay, Pierre Fabre, NAOS, Astellas, Zeldis-Pharma LLC.
Other authors confirmed the absence of a reportable conflict of interests.
Sergey P. Seleznev
Moscow Regional Research and Clinical Institute
Russian Federation
Moscow
Russian Federation
Moscow
Anait V. Tamrazova
Peoples' Friendship University of Russia;
Central State Medical Academy of Department of Presidential Affairs of the Russian Federation
Russian Federation
Moscow
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
О. Б. Тамразова — получение исследовательских грантов и гонораров за научное консультирование и чтение лекций от фармацевтических компаний Bayer, Weleda, Expanscience, Leofarma, La Roche-Posay, Pierre Fabre, NAOS, Astellas, Zeldis-Pharma LLC.
Остальные авторы статьи подтвердили отсутствие конфликта интересов, о котором необходимо сообщить.
References
1. Deleuran M, Vestergaard C. Clinical heterogeneity and differential diagnosis of atopic dermatitis. Br J Dermatol. 2014; 170 Suppl 1:2–6. doi: 10.1111/bjd.12933.
2. Tsakok T, Woolf R, Smith CH, et al. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol. 2019;180(3):464–474. doi: 10.1111/bjd.16934.
3. Garg N, Silverberg JI. Epidemiology of childhood atopic dermatitis. Clin Dermatol. 2015;33(3):281–288. doi: 10.1016/j.clindermatol.2014.12.004.
4. Kubanova AA, Kubanov AA, Melekhina LE, Bogdanova EV. The Assessment of the Incidence of Skin Disorders in Russian Federation in 2003–2016. Vestnik Dermatologii i Venerologii. 2017;(6):22–33. (In Russ). doi: 10.25208/0042-4609-2017-93-6-22-33.
5. Smirnova GI. Atopic dermatitis and skin infections in children. Rossiiskii pediatricheskii zhurnal. 2014;2:49–56. (In Russ).
6. Mier PD. Earliest description of the atopic syndrome? Br J Dermatol. 1975;92:359. doi: 10.1111/j.1365-2133.1975.tb03091.x
7. Kramer ON, Strom MA, Ladizinski B, Lio P A. The history of atopic dermatitis. Clin Dermatol. 2017;35(4):344–348. doi: 10.1016/j.clindermatol.2017.03.005.
8. Coca AF, Cooke RA. On the classification of the phenomena of hypersensitiveness. J Immunol. 1923;8(3):163–182.
9. Wise F, Sulzberger MB. Year Book of Dermatology and Syphilology. Chicago: Year Book Publishers; 1933. pp. 38–39.
10. Mayba J., Gooderham M J. (2016). Review of Atopic Dermatitis and Topical Therapies. J Cutan Med Surg. 2017;21(3):227–236. doi: 10.1177/1203475416685077.
11. Tham EH, Leung DYM. Mechanisms by Which Atopic Dermatitis Predisposes to Food Allergy and the Atopic March. Allergy Asthma Immunol Res. 2019;11(1):4–15. doi: 10.4168/aair.2019.11.1.4.
12. Atopicheskii dermatit u detei. Klinicheskie rekomendatsii. Soyuz pediatrov Rossii; Rossiiskaya assotsiatsiya allergologov i klinicheskikh immunologov; 2016. (In Russ). Доступно по: https://www.pediatr-russia.ru/information/klin-rek/deystvuyushchie-klinicheskie-rekomendatsii/АтД%20дети%20СПР.v2.pdf. Ссылка активна на 20.07.2020.
13. Fiset P-O, Leung DYM, Hamid Q. Immunopathology of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):287–290. doi: 10.1016/j.jaci.2006.03.046.
14. McGirt LY, Beck LA. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):202–208. doi: 10.1016/j.jaci.2006.04.033.
15. Cork M, Danby S, Vasilopoulos Y, et al. Epidermal Barrier Dysfunction in Atopic Dermatitis. J Invest Dermatol. 2009;129(8): 1892–1908. doi: 10.1038/jid.2009.133.
16. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–446. doi: 10.1038/ng1767.
17. Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009. J Allergy Clin Immunol. 2010; 125(1):16–29. doi: 10.1016/j.jaci.2009.11.008.
18. Eigenmann PA, Sicherer SH, Borkowski TA, et al. Prevalence of IgE mediated food allergy among children with atopic dermatitis. Pediatrics. 1998;101(3):E8. doi: 10.1542/peds.101.3.e8.
19. Suh KY. Food allergy and atopic dermatitis: separating fact from fiction. Semin Cutan Med Surg. 2010;29(2):72–78. doi: 10.1016/j.sder.2010.03.007.
20. Varlamov EE, Pampura AN, Sukhorukov VS. The Importance of Cytokines for the Atopic Dermatitis Pathogenesis. Rossiyskiy vestnik perinatologii i pediatrii. 2018;63:(1):28–33. (In Russ). doi: 10.21508/1027-4065-2018-63-1-28-33.
21. Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132(3 Pt 2):751–762. doi: 10.1038/jid.2011.393.
22. Kypriotou M, Huber M, Hohl D. The human epidermal differentiation complex: cornified envelope precursors, S100 proteins and the ‘fused genes’ family. Exp Dermatol. 2012;21(9):643–649. doi: 10.1111/j.1600-0625.2012.01472.x.
23. Gavrilova T. Immune Dysregulation in the Pathogenesis of Atopic Dermatitis. Dermatitis. 2018;29(2):57–62. doi: 10.1097/DER.0000000000000340.
24. Seltmann J, Roesner LM, Von Hesler FW, et al. IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol. 2015;135(6):1659–1661. doi: 10.1016/j.jaci.2015.01.048.
25. Tamrazova OB, Gureeva MA, Kuznetsova TA, Vorobeva AS. Age evolutionary dynamics of atopic dermatitis. Pediatriya. 2016;1:153–159. (In Russ).
26. Lee S-C. Various diagnostic criteria for atopic dermatitis (AD): A proposal of Reliable Estimation of Atopic Dermatitis in Childhood (REACH) criteria, a novel questionnaire-based diagnostic tool for AD. J Dermatol. 2016;43(4):376–384. doi: 10.1111/1346-8138.13264.
27. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh). 1980;Suppl 59:44–47.
28. Federal’nye klinicheskie rekomendatsii po vedeniyu bol’nykh atopicheskim dermatitom. Moscow: Rossiiskoe obshchestvo dermatovenerologov i kosmetologov; 2015. (In Russ).
29. Pennycook KB, McCready TA. Keratosis Pilaris. In: StatPearls [Internet]. Treasure Island (FL): StatPearls; 2019.
30. Jadotte YT, Janniger CK. Pityriasis alba revisited: perspectives on an enigmatic disorder of childhood. Cutis. 2011;87(2):66–72.
31. Miazek N, Michalek I, Pawlowska-Kisiel M, et al. Pityriasis Alba — Common Disease, Enigmatic Entity: Up-to-Date Review of the Literature. Pediatr Dermatol. 2015;32(6):786–791. doi: 10.1111/pde.12683.
32. Sarifakioglu E. Extensive pityriasis alba in a nonatopic child. Pediatr Dermatol. 2007;24(2):199–200. doi: 10.1111/j.1525-1470.2007.00379.x.
33. Lutskaya IK. Klinicheskie proyavleniya samostoyatel’nykh zabolevanii gub. Meditsinskie novosti. 2011;11:4–8. (In Russ).
34. Fenner J, Silverberg NB. Skin diseases associated with atopic dermatitis. Clin Dermatol. 2018;36(5):631–640. doi: 10.1016/j.clindermatol.2018.05.004.
35. Veien NK, Hattel T, Laurberg G. Hand eczema: causes, course, and prognosis I. Contact Dermatitis. 2008;58(6):330–334. doi: 10.1111/j.1600-0536.2008.01345.x.
36. Lerbaek A, Kyvik KO, Ravn H, et al. Clinical characteristics and consequences of hand eczema — an 8-year follow-up study of a population-based twin cohort. Contact Dermatitis. 2008;58(4): 210–216. doi: 10.1111/j.1600-0536.2007.01305.x.
37. Totte JEE, van der Feltz WT, Hennekam M, et al. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016;175(4): 687–695. doi: 10.1111/bjd.14566.
38. Wan P, Chen J, Calm A. Dispassionate Look at Skin Microbiota in Atopic Dermatitis: An Integrative Literature Review. Dermatol Ther (Heidelb). 2020;10(1):53–61. doi: 10.1007/s13555-020-00352-4.
39. Stadnikova AS, Tamrazova OB, Chebotareva TA. Clinical and anamnestic criteria for early diagnosis of herpetic eczema in children with atopic dermatitis. Almanac of Clinical Medicine. 2018;46(2):126–131. (In Russ). doi: 10.18786/2072-0505-2018-46-2-126-13.
40. Macharadze DSh. Atopic Dermatitis: New Aspects of Treatment. Current Pediatrics. 2013;12(5):80–85. (In Russ).
41. Zhernosek VF. Antileukotriene drugs in the treatment of atopic dermatitis and urticaria in children. Meditsinskie novosti. 2015;11:4–7. (In Russ).
42. Bobrova N.F. Classification (clinical-surgical) of congenital cataract. Rossiiskaya pediatricheskaya oftal’mologiya. 2012;2:52–57. (In Russ).
43. Fournie P, Touboul D, Arne JL, et al. Keratocone [Keratoconus]. J Fr Ophtalmol. 2013;36(7):618–626. doi: 10.1016/j.jfo.2013.05.004.
44. Atopicheskii dermatit. Rukovodstvo dlya vrachei / Sergeev YuV, ed. Moscow: Meditsina dlya vsekh; 2003. 183 p. (In Russ).
45. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis) in Adults and Children: Part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891.
46. Wollenberg A, Folster-Holst R, Saint Aroman M, et al. Effects of a Protein-Free Oat Plantlet Extract on Microinflammation and Skin Barrier Function in Atopic Dermatitis Patients. J Eur Acad Dermatol Venereol. 2018;32 Suppl 1:1–15. doi: 10.1111/jdv.14846.
47. Mandeau A, Aries M-F, Boe J-F, et al. Rhealba® Oat Plantlet Extract: Evidence of Protein-Free Content and Assessment of Regulatory Activity on Immune Inflammatory Mediators. Planta Med. 2011;77(9):900–906. doi: 10.1055/s-0030-1250649.
48. Saint Aroman M. News about Emollients with Rhealba Oat Plantlets Extract: Prevention and Treatment of Atopic Dermatitis. Journal of Clinical Pediatrics and Neonatal Care [Internet]. Available online: https://jacobspublishers.com/journals/journal-of-clinicalpediatrics-and-neonatal-care/fulltext/news-about-emollients-withrhealba-oat-plantlets-extract-prevention-and-treatment-of-atopicdermatitis. Accessed on July 8, 2020.
49. Aries MF, Vaissiere C, Pinelli E. Avena Rhealba inhibits A23187-stimulated arachidonic acid mobilization, eicosanoid release, and cPLA2 expression in human keratinocytes: potential in cutaneous inflammatory disorders. Biol Pharm Bull. 2005;28(4):601–606. doi: 10.1248/bpb.28.601.
50. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis) in Adults and Children: Part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878. doi: 10.1111/jdv.14888.
51. Theunis J, Chaussade H, Bourgeois O, et al. Efficacy of a Rhealba® Oat extract-based emollient on chronic pruritus in elderly French outpatients. J Eur Acad Dermatol Venereol. 2017;31 Suppl 1: 1–7. doi: 10.1111/jdv.14077.
52. Ribet V, Mielewczyk E, Sirvent A, et al. A novel dermo-cosmetic product containing thermal spring water, sucralfate, copper sulfate, and zinc sulfate in the management of hand eczema. Clin Cosmet Investig Dermatol. 2018;11:373–381. doi: 10.2147/CCID.S157849.
53. Pashinyan AG. Efficiency of dermatological cosmetic cream in patients with chronic dermatoses. Rossiyskii Zhurnal Kozhnykh i Venericheskikh Boleznei. 2015;18(4):48–55. (In Russ).
54. Renzi C, Abeni D, Picardi A, et al. Factors associated with patient satisfaction with care among dermatological outpatients. Br J Dermatol. 2001;145(4):617–623. doi: 10.1046/j.1365-2133.2001.04445.x.
55. Khlebnikova AN, Petrunin DD. The biologic role of zinc and it’s use in practical dermatology. Vestnik Dermatologii i Venerologii. 2013;6:100–116. (In Russ).
56. Brandrup F, Menne T, Agren M, et al. A randomized trial of two occlusive dressings in the treatment of leg ulcers. Acta Derm Venereol. 1990;70(3):231–235.
57. Agren M. Studies on zinc in wound healing. Acta Derm Venereol Suppl (Stockh). 1990;154:1–36.
58. Banatia A, Chowdhurya SR, Mazumderb S. Topical use of Sucralfate Cream in second and third degree burns. J Burns. 2001; 27(5):465–469. doi: 10.1016/s0305-4179(00)00165-0.
Review
For citations:
Tamrazova O.B., Seleznev S.P., Tamrazova A.V. The Role of Minor Signs in Atopic Dermatitis Diagnostics. Current Pediatrics. 2020;19(3):235-243. (In Russ.) https://doi.org/10.15690/vsp.v19i3.2120
Views:
1028
Email this article 
